Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2017

Study Completion Date

June 30, 2017

Conditions
LeishmaniasisLeishmaniasis, CutaneousLeishmaniasis; American
Interventions
DRUG

Immucillin DI4G

Immucillin DI4G was administered by topical use at 2% concentration once a day for 20 days associated with Meglumine antimoniate administered by intravenous route at a dosage of 20mg/kg/day, during 20 days.

DRUG

Meglumine antimoniate

Placebo for topical use once a day at the ulcer for 20 days associated with Meglumine antimoniate administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.

Trial Locations (1)

40000

Corte de Pedra Health Post, Corte de Pedra

All Listed Sponsors
collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico

OTHER_GOV

collaborator

Federal University of Bahia

OTHER

collaborator

Pontificia Universidade Católica do Rio Grande do Sul

OTHER

lead

Hospital Universitário Professor Edgard Santos

OTHER

NCT03294161 - Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis | Biotech Hunter | Biotech Hunter